Casimersen Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The global Casimersen market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Caspersen uses the chemistry of Sarepta’s phosphorodiamidate morpholino oligomer (PMO) and exon-skipping technology to bypass the exon 45 DMD gene and it is designed to bind to exon 45 of dystrophin pre-mRNA, which leads to release, this exon during mRNA analysis in patients with genetically modified mutations 45. The increase in the prevalence of muscle disease has created a demand for the development of new for its treatment which in turn drives the global casimersen market growth. In addition, leading pharmaceutical companies are focusing on the development of casimersen for Duchennemuscular dystrophy (DMD) treatment, and the market growth is driven by the strong focus of the pharmaceutical companies and research organizations on the R&D of mutation for the casimersen market.

However, the rising costs of treatments along with stringent regulatory policies related to this casimersen drug usage are expected to hamper the casimersen market growth and the emerging economies that are focusing on healthcare development are expected to offer lucrative opportunities for the growth of the casimersen market. Sarepta Therapeutics, Inc., NS Pharma, Inc., PTC Therapeutics, Inc., and Pfizer Inc., are the key market players that are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships, and collaborations, and new product launches. For instance, in April 2018, Milo Biotechnology was one of the first companies to enter DMD gene therapy. Moreover, the company’s investigative treatment uses an adeno-related virus as a myostatin inhibitor and is in the early stages of development and the Wave Life Science plumbing product is likely to perform 25 times better in terms of clinical efficacy than existing overdose drugs, which increased the demand of casimersen market across the globe.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Sarepta Therapeutics, Inc., NS Pharma, Inc., PTC Therapeutics, Inc., Pfizer Inc., and Cipla Inc. Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global CasimersenMarket Report by Segment

By Type

• Capsule
• Injection
• Others

By Application

• Hospital
• Clinical
• Others